AR066936A1 - 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas. - Google Patents
3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.Info
- Publication number
- AR066936A1 AR066936A1 ARP080102458A ARP080102458A AR066936A1 AR 066936 A1 AR066936 A1 AR 066936A1 AR P080102458 A ARP080102458 A AR P080102458A AR P080102458 A ARP080102458 A AR P080102458A AR 066936 A1 AR066936 A1 AR 066936A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- tetrahydrofuryl
- thioxanthin
- thioxantine
- tetrahydrofuril
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
Abstract
Reivindicacion 1: La Forma A de 3-(2R-tetrahidrofuril-metil)-2-tioxantina. Reivindicacion 2: La Forma A de 3-(2R-tetrahidrofuril-metil)-2-tioxantina, caracterizada por proporcionar un patron de difraccion de rayos X de muestras en polvo que exhibe sustancialmente los siguientes valores de d: Reivindicacion 14: La forma B de 3-(2R-tetrahidrofuril-metil)-2-tioxantina segun la reivindicacion 13, caracterizada por valores °2theta de difraccion de rayos X de muestras en polvo de 16.56, 24.86 y 29.07 °2theta. Reivindicacion 26: El uso de una mezcla de 3-(2R-tetrahidrofuril-metil)-2-tioxantina segun cualquiera de las reivindicaciones 1-5 y de 3-(2R-tetrahidrofuril-metil)-2-tioxantina segun cualquiera de las reivindicaciones 11-15 como ingredientes activos en la fabricacion de un medicamento para su uso en el tratamiento o profilaxis de enfermedades o condiciones en las que la inhibicion de la enzima MPO es beneficiosa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94367107P | 2007-06-13 | 2007-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR066936A1 true AR066936A1 (es) | 2009-09-23 |
Family
ID=39744966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080102458A AR066936A1 (es) | 2007-06-13 | 2008-06-09 | 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas. |
Country Status (19)
Country | Link |
---|---|
US (1) | US20080312311A1 (es) |
EP (1) | EP2158202A1 (es) |
JP (1) | JP2010529185A (es) |
KR (1) | KR20100020002A (es) |
CN (1) | CN101679435A (es) |
AR (1) | AR066936A1 (es) |
AU (1) | AU2008263582A1 (es) |
BR (1) | BRPI0812480A2 (es) |
CA (1) | CA2690468A1 (es) |
CL (1) | CL2008001766A1 (es) |
CO (1) | CO6251290A2 (es) |
EC (1) | ECSP109874A (es) |
IL (1) | IL202281A0 (es) |
MX (1) | MX2009013126A (es) |
PE (1) | PE20090367A1 (es) |
RU (1) | RU2010100484A (es) |
TW (1) | TW200916096A (es) |
UY (1) | UY31139A1 (es) |
WO (1) | WO2008152420A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR039385A1 (es) * | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
WO2010068171A1 (en) * | 2008-12-12 | 2010-06-17 | Astrazeneca Ab | A process for the preparation of 3- [ (2r) tetrahydrofuran-2- ylmethyl] -2-thioxo-l, 2, 3, 7-tetrahydro-6h-purin-6-one |
CN110891572B (zh) | 2017-07-17 | 2023-08-15 | 阿斯利康(瑞典)有限公司 | 用于医学的mpo抑制剂 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR039385A1 (es) * | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
SE0302756D0 (sv) * | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel Compounds |
JP2009533426A (ja) * | 2006-04-13 | 2009-09-17 | アストラゼネカ・アクチエボラーグ | チオキサンチン誘導体およびそれらのmpo阻害剤としての用途 |
UY30267A1 (es) * | 2006-04-13 | 2007-11-30 | Astrazeneca Ab | Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones |
-
2008
- 2008-06-09 AR ARP080102458A patent/AR066936A1/es unknown
- 2008-06-11 AU AU2008263582A patent/AU2008263582A1/en not_active Abandoned
- 2008-06-11 EP EP08762543A patent/EP2158202A1/en not_active Withdrawn
- 2008-06-11 JP JP2010511729A patent/JP2010529185A/ja active Pending
- 2008-06-11 UY UY31139A patent/UY31139A1/es unknown
- 2008-06-11 RU RU2010100484/04A patent/RU2010100484A/ru not_active Application Discontinuation
- 2008-06-11 BR BRPI0812480A patent/BRPI0812480A2/pt not_active IP Right Cessation
- 2008-06-11 CA CA2690468A patent/CA2690468A1/en not_active Abandoned
- 2008-06-11 WO PCT/GB2008/050433 patent/WO2008152420A1/en active Application Filing
- 2008-06-11 CN CN200880020106A patent/CN101679435A/zh active Pending
- 2008-06-11 KR KR1020097025947A patent/KR20100020002A/ko not_active Application Discontinuation
- 2008-06-11 MX MX2009013126A patent/MX2009013126A/es not_active Application Discontinuation
- 2008-06-12 TW TW097121960A patent/TW200916096A/zh unknown
- 2008-06-12 US US12/137,583 patent/US20080312311A1/en not_active Abandoned
- 2008-06-13 PE PE2008001012A patent/PE20090367A1/es not_active Application Discontinuation
- 2008-06-13 CL CL2008001766A patent/CL2008001766A1/es unknown
-
2009
- 2009-11-23 IL IL202281A patent/IL202281A0/en unknown
- 2009-12-09 CO CO09140840A patent/CO6251290A2/es not_active Application Discontinuation
-
2010
- 2010-01-13 EC EC2010009874A patent/ECSP109874A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2158202A1 (en) | 2010-03-03 |
CL2008001766A1 (es) | 2008-12-19 |
CA2690468A1 (en) | 2008-12-18 |
WO2008152420A1 (en) | 2008-12-18 |
PE20090367A1 (es) | 2009-04-15 |
TW200916096A (en) | 2009-04-16 |
MX2009013126A (es) | 2010-01-15 |
US20080312311A1 (en) | 2008-12-18 |
RU2010100484A (ru) | 2011-07-20 |
AU2008263582A1 (en) | 2008-12-18 |
IL202281A0 (en) | 2010-06-16 |
KR20100020002A (ko) | 2010-02-19 |
ECSP109874A (es) | 2010-02-26 |
CO6251290A2 (es) | 2011-02-21 |
UY31139A1 (es) | 2009-01-30 |
CN101679435A (zh) | 2010-03-24 |
JP2010529185A (ja) | 2010-08-26 |
BRPI0812480A2 (pt) | 2017-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY37461A (es) | 1,2,4 – triazolonas 2,4,5 trisustituida | |
ECSP17007538A (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
GT201400111A (es) | Triazolopiridinas sustituidas | |
CR20140113A (es) | Imidazopiridazinas sustituidas con amino | |
CR10192A (es) | Compuestos de amido y su uso como productos farmaceuticos | |
CR20140392A (es) | Dihidropirazolonas sustituidas | |
UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
CO6410279A2 (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
PA8660301A1 (es) | Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion | |
AR068369A1 (es) | Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina" | |
AR058098A1 (es) | Derivados de acidos dicarboxilicos y su uso | |
UY35293A (es) | Isotiazoles sustituidos con amino | |
CL2010001348A1 (es) | Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad. | |
CO6690805A2 (es) | 6-amino-nicotinamidas sustituidas como modulares de kcnq2/3 | |
DOP2009000287A (es) | Oxazolidinonas sustituidas y su uso | |
UY31133A1 (es) | "oxazolidinonas sustituidas y su uso" | |
ME01456B (me) | Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola | |
CU20120171A7 (es) | Triazolopiridinas sustituidas | |
UY29343A1 (es) | Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso. | |
CO6511222A2 (es) | Derivado de idenona y composición famacéutica que comprende el mismo | |
AR066936A1 (es) | 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas. | |
CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
CU24011B1 (es) | Piperidinas 2-fenil-5-(1,2,4-oxadiazol-5-il) sustituidas | |
UY31143A1 (es) | Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |